Farydak

Active Ingredient(s): Panobinostat
FDA Approved: * February 23, 2015
Pharm Company: * NOVARTIS PHARMS CORP
Category: Cancer

Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of various cancers. It is a hydroxamic acid[2] and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).[3] On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma,[4][5] and on 28 August 2015 it was approved by the European Medicines Agency for the same use.[6] ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Farydak 10 mg Oral Capsule
NDC: 0078-0650
Labeler:
Novartis Pharmaceuticals Corporation
Farydak 15 mg Oral Capsule
NDC: 0078-0651
Labeler:
Novartis Pharmaceuticals Corporation
Farydak 20 mg Oral Capsule
NDC: 0078-0652
Labeler:
Novartis Pharmaceuticals Corporation
Farydak 10 mg Oral Capsule
NDC: 73116-100
Labeler:
Secura Bio, Inc.
Farydak 15 mg Oral Capsule
NDC: 73116-101
Labeler:
Secura Bio, Inc.
Farydak 20 mg Oral Capsule
NDC: 73116-102
Labeler:
Secura Bio, Inc.